Biological agents: New drugs, old problems

Journal of Allergy and Clinical Immunology

Volumn 126, Issue 2, 2010, Pages 394-395

  Muńoz Cano, Rosa ^a   Carnés, Jerónimo ^b   Sanchez Lopez, Jaime ^a   Saiz, Albert ^c   Bartra, Joan ^a   Lopez Matas, M Angeles ^b   Picado, Cesar ^a   Valero, Antonio ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b ASING SL   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955926413     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2010.05.004     Document Type: Letter

References (8)

1. Pichler WJ. Adverse side-effects to biological agents. Allergy 2006;61:912-20.
2. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002;57:45-51.
3. Commins SP, Platts-Mills TA. Anaphylaxis syndromes related to a new mammalian cross-reactive carbohydrate determinant. J Allergy Clin Immunol 2009;124:652-7.
4. Yednock T (2007) inventor; Elan Pharmaceuticals, Inc, assignee. Methods of treating inflammatory and autoimmune diseases with Natalizumab. International patent application WO/2007/103112.
5. Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007;69:1391-403.
6. Killestein J, Jasperse B, Liedorp M, Seewann A, Polman CH. Very late delayed- allergic reaction to natalizumab not associated with neutralizing antibodies. Multiple Sclerosis 2009;15:525-6.
7. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3- galactose. N Engl J Med 2008;58:1109-17.
8. Price KS, Hamilton RG. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc 2007;28:313-9.